All Industries

Top Oncology Companies

119 Oncology companies, sorted by total funding raised.

Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech, Oncology
Series B·$446.0M·Sep 2025
ArcellxIPO

Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable...

Redwood City51–200Biopharmaceutical, Oncology
Seed·$375.0M·Jan 2024
Pathos

Pathos is an AI-enabled biotechnology company focused on re-engineering drug development.

Chicago, United States51–200Artificial Intelligence, Biotech
Series D·$365.0M·May 2025
Oricell Therapeutics

Clinical-stage oncology company developing novel CAR-T cell therapies for hematological malignanc...

Shanghai, China51–200Oncology, Therapeutics
Venture Unknown·$364.0M·Apr 2026
ArriVentIPO

Clinical-stage biopharma developing and commercializing oncology therapeutics, partnering to glob...

Newtown Square, United States11–50Life Sciences, Biotech
Series B·$305.0M·Mar 2023
Concert AI

Provides AI and real-world oncology data solutions to life sciences companies, accelerating clini...

Boston, United States1001–5000Artificial Intelligence, Healthcare
Series C·$300.0M·Mar 2022
Harbinger Health

Cancer detection company pioneering early cancer screening using AI and biology of cancer origin.

United StatesArtificial Intelligence, Healthcare
Series C·$290.0M·Apr 2026
AbbiskoIPO

Shanghai-based oncology biotech discovering precision and immuno-oncology therapeutics for cancer...

Shanghai, China201–500Biotech, Oncology
Series D·$263.0M·Jan 2021
AntengeneIPO

Commercial-stage biopharmaceutical company developing first-in-class therapeutics for hematologic...

Shanghai, China201–500Biotech, Oncology
Series C·$238.0M·Jul 2020
Alterome TherapeuticsAcquired

Clinical-stage precision oncology company developing alteration-specific therapeutics for cancer ...

San Diego, United States11–50Biotech, Oncology
Series B·$231.0M·Apr 2024
Galvanize Therapeutics

Galvanize Therapeutics is a leader in energy-based medical device technology that impacts biologi...

Redwood City, United States51–200Medical Devices, Medtech
Series C·$210.0M·Sep 2025
MEI PharmaIPO

Oncology company focused on the clinical development of novel therapies for cancer

San Diego, United States11–50Biotech, Oncology
Private Equity·$202.5M·Jul 2025
CARGO Therapeutics

Clinical-stage biotech engineering best-in-class CAR T-cell therapies to overcome resistance to c...

San Carlos, United States51–200Biotech, Healthcare
Venture Unknown·$200.0M·Mar 2023
Callio Therapeutics

Callio Therapeutics is developing next‐generation dual‐payload antibody drug conjugates (ADCs) fo...

Seattle, United States1–10Biotech, Oncology
Series A·$187.0M·Mar 2025
Black Diamond TherapeuticsIPO

Black Diamond discovers and develops next-wave precision cancer medicines to treat patients with ...

Cambridge, United States51–200Biotech, Oncology
Series C·$170.0M·Dec 2019
AVEO OncologyAcquired

Commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines th...

Boston, United States51–200Biotech, Oncology
Venture Unknown·$151.0M
Clovis OncologyIPO

Focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Eur...

Boulder, United States201–500Biotech, Oncology
Series A·$145.0M·May 2009
Sidewinder Therapeutics

Pioneering the next generation of large molecule precision therapeutics to deliver new life-savin...

United StatesBiotech, Oncology
Series B·$137.0M
Elephas Biosciences

Biosciences company developing precision oncology platforms; headquartered in Madison, Wisconsin.

Madison, United StatesBiotech, Oncology
Extension Round·$136.5M·Nov 2025
Atreca

Biopharma startup developing cancer treatments based on human immune response.

Redwood City, United States11–50Biotech, Oncology
Series C·$125.0M·Sep 2018
Atomwise

Artificial intelligence for drug discovery.

San Francisco, United States51–200Biotech, Artificial Intelligence
Series B·$123.0M·Aug 2020
MediLink Therapeutics

Innovative ADC drug development company focused on next-generation antibody-drug conjugates for c...

Suzhou, ChinaAntibody Drug Conjugates, Oncology
Series B·$120.0M·Mar 2022
Nkarta TherapeuticsIPO

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural ...

South San Francisco, United States51–200Biotech, Oncology
Series B·$114.0M·Sep 2019
Atara BiotherapeuticsIPO

Clinical-stage allogeneic T-cell immunotherapy company developing off-the-shelf cell therapies fo...

Thousand Oaks, United States201–500Biotech, Immunotherapy
Series B·$110.5M·Jan 2014
Dispatch Biotherapeutics

Clinical-stage immunotherapy company developing the Flare platform to expand curative potential o...

Biotech, Immunotherapy
Series A·$106.0M·Jul 2025